Zimmer Biomet Q2 revenue beats on technology, data growth
ZBH•Analyst view
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 8 "strong buy" or "buy", 21 "hold" and no "sell" or "strong sell".
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."
Wall Street's median 12-month price target for Zimmer Biomet Holdings, Inc. is $95.00, about 0.8% below its August 4 closing price of $95.81. The stock recently traded at 11 times the next 12-month earnings versus a P/E of 10 three months ago.
Full-year outlook raised
Zimmer Biomet raised its full-year 2026 reported revenue growth guidance to 3.9%-4.9%. The company now sees 2026 adjusted diluted EPS at $8.47-$8.59.
Zimmer Biomet said healthy markets and its innovation cycle are driving the improved outlook, and it plans up to $1 bln in share buybacks.
Q2 results beat estimates
Zimmer Biomet said second-quarter revenue rose 4.8% and beat analyst expectations. Adjusted earnings per share for the quarter were flat year over year but also beat analyst expectations.
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Sales | Beat | $2.18 bln | $2.13 bln (23 Analysts) |
| Q2 Adjusted EPS | Beat | $2.07 | $2.009 (23 Analysts) |
| Q2 EPS | $1.03 | ||
| Q2 Net Income | $198.30 mln |
